William Blair analyst Andrew Brackmann has maintained their bullish stance on DGX stock, giving a Buy rating on October 17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Brackmann has given his Buy rating due to a combination of factors that highlight Quest Diagnostics’ strong performance and promising outlook. The company delivered positive results in its third-quarter report, surpassing expectations across key metrics. This performance was driven by several favorable trends, including increased utilization, stable pricing, and successful mergers and acquisitions.
Quest Diagnostics also demonstrated impressive organic revenue growth, which exceeded consensus estimates. The company’s adjusted operating margin and earnings per share were in line with or above expectations, further solidifying its financial health. Additionally, the company raised its full-year guidance, indicating confidence in continued growth. These factors collectively justify the premium valuation of Quest Diagnostics’ shares, supporting the Buy rating.
In another report released on October 17, Mizuho Securities also maintained a Buy rating on the stock with a $210.00 price target.